CVS Health Payor Solutions
Payor Solutions
Main menu
Biosimilars
About
Our Story
Who We Serve
Integrated Assets
Insights
All Insights
Care Management
Cost Management
Drug Pipeline
GLP-1s
Government Programs & Services
Health Equity
Innovation
Public Policy
Specialty
Women's Health
Contributors
Programs & Services
Overview
Cost Management
Formulary Management
Network Strategies
Hyperinflation
Gene Therapy Solutions
Member Affordability
Specialty Management
Specialty Cost Management
Medical Benefit Solutions
Transform Oncology Care
Patient Care
Radiation Oncology
Care Management
Member Engagement
Onboarding
Benefit Plan Changes
Health Plan Client Engagement
Shortcuts
Contact Us
Resources
Videos
News
Webinars
Events
Other Sites
Client Care Access
CVS Health
CVS Caremark
CVS Specialty
CVS Pharmacy
CVS MinuteClinic
Search form
Search
“Biosimilars”
18 result(s)
Format
All Formats
Briefing
Commentary
Feature
Infographic
Specialty Report
Video
White Paper
Sort by
Most Recent
Most Popular
Drug Pipeline
Increasing Provider Understanding of Biosimilars with Proactive Outreach
Increasing Provider Understanding of Biosimilars with Proactive Outreach
More
Briefing
Specialty
7 Stats That Show What Providers Think About Biosimilars
7 stats that show what providers think about biosimilars
More
Briefing
Drug Pipeline
The Dynamic Biosimilars Market
The Dynamic Biosimilars Market
More
Video
Drug Pipeline
Optimizing Treatment for Inflammatory Bowel Disease
New Drugs and Tools to Optimize IBD Treatment
More
Briefing
Specialty
The Impact of Autoimmune Conditions on Women
Women are overrepresented among autoimmune patients so may benefit the most from new biosimilar treatments
More
Briefing
Specialty
Member Education: How We Help Build Awareness
Supporting members through prescription changes with CVS Health’s many touchpoints, expertise, and data
More
Briefing
Drug Pipeline
Biosimilars in the Autoimmune Category
Biosimilars in the Autoimmune Category
More
Briefing
Specialty
The First Biosimilar to Humira Is Here. Now What?
The First Biosimilar to Humira Is Here
More
Briefing
Drug Pipeline
Keeping an Eye on the Drug Pipeline
New Drugs for Ophthalmic Disorders on the Horizon
More
Briefing
Drug Pipeline
Expanding Therapies, Indications and Implications for Payors
2022 Marketplace Outlook: Expanding Therapies, Indications and Implications for Payors
More
Briefing
Load More